These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 18325904)
1. Misleading congress about drug development: Reply. Dimasi JA; Hansen RW; Grabowski HG J Health Polit Policy Law; 2008 Apr; 33(2):319-24; discussion 325-7. PubMed ID: 18325904 [TBL] [Abstract][Full Text] [Related]
2. America's other drug problem: how the drug industry distorts medicine and politics. Relman AS; Angell M New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803 [No Abstract] [Full Text] [Related]
3. Congress has its brain on drug benefits. Birnbaum JH Fortune; 2003 Jan; 147(1):178. PubMed ID: 12602124 [No Abstract] [Full Text] [Related]
4. The economics of priority review vouchers. Dimitri N Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445 [TBL] [Abstract][Full Text] [Related]
5. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999 [TBL] [Abstract][Full Text] [Related]
6. The state of innovation in drug development. Kola I Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690 [TBL] [Abstract][Full Text] [Related]
7. US presidential candidates diverge on how to help biopharma. Matthews S Nat Med; 2012 Oct; 18(10):1445. PubMed ID: 23042331 [No Abstract] [Full Text] [Related]
8. In search of sustainability: process R&D in light of current pharmaceutical industry challenges. Federsel HJ Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405 [TBL] [Abstract][Full Text] [Related]
9. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008. Shumoogam J; Al-Shamahi A IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677 [TBL] [Abstract][Full Text] [Related]
10. GAO report says drug R & D costs rising, innovation decreasing. Consult Pharm; 2007 Mar; 22(3):257-8. PubMed ID: 17691159 [No Abstract] [Full Text] [Related]
11. Examining the link between price regulation and pharmaceutical R&D investment. Vernon JA Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673 [TBL] [Abstract][Full Text] [Related]
12. Portfolio analysis and R&D decision making. Evans R; Hinds S; Hammock D Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818 [No Abstract] [Full Text] [Related]
15. Foreign free riders and the high price of US medicines. Light DW; Lexchin J BMJ; 2005 Oct; 331(7522):958-60. PubMed ID: 16239695 [TBL] [Abstract][Full Text] [Related]
16. Time for a medical. Nature; 2007 May; 447(7144):507-8. PubMed ID: 17538577 [No Abstract] [Full Text] [Related]
17. Comparative effectiveness casts first shadows across US industry. Waltz E Nat Biotechnol; 2009 Mar; 27(3):211-2. PubMed ID: 19270651 [No Abstract] [Full Text] [Related]
18. Research funding. Politics and funding in the U.S. public biomedical R&D system. Hegde D; Mowery DC Science; 2008 Dec; 322(5909):1797-8. PubMed ID: 19095928 [No Abstract] [Full Text] [Related]